首页> 外文学位 >Serum 25-hydroxyvitamin D response to daily oral supplementation with 800 IU cholecalciferol in premenopausal women living in Maine
【24h】

Serum 25-hydroxyvitamin D response to daily oral supplementation with 800 IU cholecalciferol in premenopausal women living in Maine

机译:居住在缅因州的绝经前妇女每天口服800 IU胆钙化固醇对血清25-羟基维生素D的反应

获取原文
获取原文并翻译 | 示例

摘要

The purpose of this research was to measure the serum 25-hydroxyvitamin D [25(OH)D] response to daily supplementation with 800 IU vitamin D3 during winter in premenopausal women living in Maine, and to examine the effects of body composition and hormonal contraceptive use on baseline serum 25(OH)D levels and the response to supplementation.;One hundred twelve women (22.2+/-3.7 years old) received placebo from March 2005 until September 2005 when they were randomized to receive either placebo or 800 IU vitamin D3 through February 2006. Eighty-six women completed the study. Body composition was measured by dual-energy x-ray absorptiometry. Actual vitamin D3 content of the supplements averaged 885 IU per capsule.;In February 2005 the mean+/-SD serum 25(OH)D was 62.0+/-23.4 nmol/L in all subjects. Twenty-nine percent of subjects had optimal serum 25(OH)D levels (≥75 nmol/L). Serum 25(OH)D levels were significantly higher (p < 0.0005) in the 58 hormonal contraceptive users (68.6+/-24.0 nmol/L) than in the 28 non-users (48.3+/-14.8 nmol/L). The 25(OH)D concentration increased with estrogen dose. Subjects in the highest tertile body fat (>33%) had significantly lower serum 25(OH)D levels (47.8+/-17.3 nmol/L) than subjects in the middle and lowest tertiles (69.4+/-23.8 and 69.0+/-22.2 nmol/L). Estrogen dose, percent body fat and alcohol consumption were significant predictors of February 2005 serum 25(OH)D levels.;Serum 25(OH)D levels increased by 35.3+/-23.2 nmol/L from February 2005 to February 2006 in the treatment group, compared to 10.9+/-16.9 nmol/L in the placebo group. Treatment group, magnitude of summer increase in 25(OH)D, estrogen dose, and baseline serum 25(OH)D levels, but not body fat, were significant predictors of the one-year change in 25(OH)D levels.;Daily supplementation with 800 IU vitamin D3 during winter achieved optimal 25(OH)D levels (≥75 nmol/L) in 80% of subjects, indicating that this dose is too low to optimize vitamin D status in the population as a whole. Body fat does not appear to influence the serum 25(OH)D response to supplementation with vitamin D3, except through its influence on the baseline serum 25(OH)D level. Further research is needed to determine whether there is a health benefit to the higher serum 25(OH)D levels in oral contraceptive users.
机译:这项研究的目的是测量在缅因州绝经前妇女冬季冬季每天补充800 IU维生素D3对血清25-羟基维生素D [25(OH)D]的反应,并研究人体成分和激素避孕药的影响从2005年3月至2005年9月,随机选择接受安慰剂或800 IU维生素的基线水平的血清25(OH)D水平和对补充的反应; 112名妇女(22.2 +/- 3.7岁)接受了安慰剂。 D3截止到2006年2月。86名妇女完成了研究。身体成分通过双能X射线吸收法测量。补充剂的实际维生素D3含量平均为每胶囊885 IU。; 2005年2月,所有受试者的平均+/- SD血清25(OH)D为62.0 +/- 23.4 nmol / L。 29%的受试者的最佳血清25(OH)D水平(≥75nmol / L)。 58位激素避孕药使用者(68.6 +/- 24.0 nmol / L)的血清25(OH)D水平显着高于28位非激素避孕药使用者(48.3 +/- 14.8 nmol / L)(p <0.0005)。 25(OH)D浓度随雌激素剂量的增加而增加。最高三分位数体脂(> 33%)的受试者的血清25(OH)D水平(47.8 +/- 17.3 nmol / L)显着低于中三分位数和最低三分位数的受试者(69.4 +/- 23.8和69.0 + / -22.2nmol / L)。从2005年2月至2006年2月,治疗中血清25(OH)D水平显着预测了雌激素剂量,人体脂肪和酒精消耗百分比;血清25(OH)D水平增加了35.3 +/- 23.2 nmol / L。相比之下,安慰剂组为10.9 +/- 16.9 nmol / L。治疗组,夏季25(OH)D升高的幅度,雌激素剂量和基线血清25(OH)D水平(而非体脂)是25(OH)D一年变化的重要预测指标。在冬季每天补充800 IU维生素D3可在80%的受试者中达到最佳25(OH)D水平(≥75nmol / L),表明该剂量太低,无法整体上优化维生素D的状况。体脂似乎不影响补充维生素D3对血清25(OH)D的反应,除非它对基线血清25(OH)D水平有影响。需要进一步的研究来确定口服避孕药使用者较高的血清25(OH)D水平是否对健康有益。

著录项

  • 作者

    Nelson, Monica.;

  • 作者单位

    The University of Maine.;

  • 授予单位 The University of Maine.;
  • 学科 Nutrition.
  • 学位 Ph.D.
  • 年度 2007
  • 页码 187 p.
  • 总页数 187
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:39:23

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号